Melodi Health announced two milestones: the close of a $10.75 million oversubscribed Series A financing; and the launch of the 'ARIA' investigational device exemption (IDE) trial aimed at improving clinical outcomes for women undergoing breast reconstruction after mastectomy. The company is committed to developing medical products that transform breast reconstruction and impact women undergoing treatment for breast cancer.

The Series A proceeds will be used to fund clinical activities and additional product development activities. Melodi Health has raised $15 million since its founding in February 2021. Series A investors include HM Venture Partners, Engage Venture Partners, Southeast Minnesota Capital Fund, and Three Bridges Private Capital.

Melodi Health is committed to transforming breast reconstruction through surgical innovation with the aim to meaningfully improve outcomes in a patient population that is undergoing complicated treatment regimens. Melodi's flagship offering, the Melodi Matrix, is based on proven technology from Medtronic. The Melodi Matrix is a bioabsorbable mesh that elutes antibiotic agents and is fully absorbed by the body. Melodi has licensed Medtronic technology for the breast surgery field of use.